Having trouble viewing this email? View in your browser.
ESCMID Logo

25 June 2019
WEEKLY NEWS

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,

ESCMID Executive Office.

 

The EU Council approved and publish the “Conclusions on the next steps towards making the EU a best practice region in combatting antimicrobial resistance”

On 26 March 2019, the Romanian presidency of the Council of the European Union (EU) submitted a “Draft conclusions on the next steps towards making the EU a best practice region in combatting antimicrobial resistance” to the Council. Starting from June 2019, the final document is approved and adopted. ESCMID strongly contributed to the work of the EU presidency in the elaboration of this text and we proudly announce that several of ESCMID suggestions have been taken on board. For further details, please find here the complete official document.

› Read more

Second ESCMID Course on Precision Medicine – Attendance Grants available

Don’t miss out on applying for an attendance grant for the Second ESCMID course on Precision Medicine, to be held in Rome, Italy in September 2019! – Learn from a faculty of international experts about the specifics of treating special patient populations.

Grant applications close on 1 July 2019.

› Read more

IMMEM XII earlybird deadline and Late-breaking abstracts closing soon!

Don’t miss out on the discounted earlybird rates for the 12th International Meeting on Microbial Epidemiological Markers (IMMEM XII), to be held from 18-21 September 2019 in Dubrovnik, Croatia. Registration fees increase after the 30th of June, so register now to secure the discounted rate! Late-breaking abstracts are also being accepted for inclusion in the meeting programme.

Find out more on the conference website.

› Read more
 

CMI highlight: Are Nontreponemal Tests Suitable for Monitoring Syphilis Treatment Efficacy? Evidence from Rabbit Infection Models

LR. Lin et al. aimed to characterize kinetics of nontreponamal antibody titer during the natural syphilitic course and explore their roles in monitoring syphilis treatment efficacy.

Sixty New Zealand white male rabbits were challenged with the Nichols or Amoy T. pallidum strains, and rapid plasma reagin (RPR) test was performed to quantify nontreponemal antibody titers during the infection course. Viable T. pallidum in the challenged rabbits was assessed with rabbit infectivity tests.

The RPR titers of the Nichols or Amoy strain between no BPG and BPG treatment subgroups were observed similar trend: first ascended and then descended. Compared to baseline, the proportions of fourfold-decline in RPR titers in the Nichols or Amoy group presented a similar result on day 30, 60 and 180 between no BPG and BPG treatment subgroups [(00% (0/5), 80% (4/5),100% (5/5)) vs (00% (0/5), 80% (4/5), 100% (5/5)), P=0.999; (00% (0/5) , 80% (4/5), 80% (4/5)) vs (40% (2/5), 100% (5/5), 100% (5/5)), P=0.098, respectively]. And compared to the maximum baseline titer, the proportion of fourfold-decline in PRR titer also showed a similar result in the two groups on day 30, 60 and 180 between no BPG and BPG treatment subgroups [(0% (0/5), 100% (5/5), 100% (5/5)) vs (40% (2/5), 100% (5/5), (100% (5/5), P=0.129); (0% (0/5), 100% (5/5), 100%(5/5)) vs (80% (4/5), 100% (5/5), 100% (5/5), P=0.091), respectively]. Moreover, regardless of whether the RPR titers presented a fourfold-decline, viable T. pallidum could be detected in untreated rabbits’ lymph nodes at 30, 60 and 180 d post infection, while viable T. pallidum was not detected in any of the treated rabbits’ lymph nodes.

The authors concluded that the RPR titer increased and then decreased (even became negative) during the natural syphilitic course, similar to that seen after BPG treatment. The RPR titer is thus a questionable indicator of syphilis treatment efficacy.

› Read more
 

European Commission panels on medical devices and in vitro diagnostic devices: call for clinical and other experts to be published later in 2019!

The new EU regulations on medical devices and in vitro diagnostics came into force in 2017. They stipulate the establishment of expert panels to support the assessment of specific high-risk devices and to contribute to the prospective improvement of the overall framework by advising the Commission, the Medical Device Coordination Group, Member States, Notified Bodies and manufacturers. The call for clinical and other experts in the area of medical devices and in vitro diagnostic devices will be launched later in 2019 and published in the Official Journal of the European Commission. For further details please refer to the official European Commission document and visit the European Commission website on Medical Devices.

› Read more
 

EUCIC launches a survey on Influenza vaccination!

Health care workers (HCWs) are at risk for infection by influenza. For this reason, the annual influenza vaccine is recommended for HCWs not only to protect themselves but also to protect other HCWs and, most importantly, their patients. However, influenza vaccination rates among HCWs are usually lower than expected, with variations and differences observed between countries. The hospital infection control teams have a potential to change HCWs’ attitude and practices towards influenza vaccination. Through this survey, performed by the European Committee on Infection Control (EUCIC), available in 11 languages (Croatian, Dutch, English, French, German, Greek, Italian, Romanian, Russian, Spanish, Turkish), we aim to understand the attitudes of the infection control teams on influenza vaccination in different countries and their rationale for accepting or rejecting influenza vaccination. Results and conclusions derived from this survey will help shape future strategies.
The survey will be open until 15 July 2019. We look forward to your feedback and participation in this exciting initiative! Thank you for your contribution and commitment in advance. If you have further questions feel free to contact us at any time EUCIC@escmid.org

On behalf of the EUCIC working group (Önder Ergönül, Şiran Keske, Nico T. Mutters, Constantinos Tsioutis) and translators (Gabriel Birgand, Elena Carrara, Edwina Doting, Juan Pablo Horcajada, Tomislav Mestrovic, Natalia Pshenichnaya, Oana Sandulescu)

› Read more
 

MSF France Vacancy: Tropical Infectious Diseases advisor (M/F)

Médecins Sans Frontičres (MSF) is an international, independent, medical humanitarian organization created in 1971 that delivers emergency aid to people affected by armed conflict, epidemics, healthcare exclusion and natural disasters. MSF offers assistance to people based only on need and irrespective of race, religion, gender or political affiliation. The French section is present in around thirty countries. As part of a permanent replacement, the MSF-Operational Centre Paris (MSF-OCP) Medical Department is looking for a Tropical Infectious Diseases Advisor to enhance MSF’s ability to effectively diagnose and treat tropical diseases. Please follow this link to read more and to send your application.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.